PHAT
Phathom Pharmaceuticals, Inc. Common Stock
stockNASDAQ
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 7.35 | 2026-09-28 | -7.89% | -2.188 |
| 1M | 9.50 | 2026-09-04 | -28.74% | 2.073 |
| 3M | 11.38 | 2026-07-06 | -40.51% | -0.072 |
| 6M | 11.25 | 2026-04-06 | -39.82% | 0.103 |
| 1Y | 11.61 | 2025-10-06 | -41.69% | 0.592 |
| 2Y | 17.25 | 2024-10-04 | -60.75% | — |
| 5Y | 32.15 | 2021-10-05 | -78.94% | 1.333 |
Phathom Pharmaceuticals, Inc. Common Stock (NASDAQ:PHAT) stock price today is $6.77, and today's volume is 201,345. PHAT is down 2.168% today. The 30 day average volume is 1.20M. PHAT market cap is $547.70M with 80.90M shares outstanding.